insights_auto
Nega 2X1 oshdi 2,86%?
Batafsil oʻrganishchevron_right
2X1:ETR
Abivax SA
79,00 €
arrow_upward
+2,86%(+2,20) 1K
9-okt, 17:35:37 (GMT+2) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto2X1 tikeri uchun statistika yaratilmoqda...
Ochish
78,95 €
Yuqori
80,40 €
Past
78,95 €
Bozor kapitali
6,81 mlrd
Oʻrtacha hajm
1,81 ming
Hajmi
189,00
52 haftalik eng yuqori
137,40 €
52 haftalik eng past
60,85 €
Aksiya boʻyicha daromad
-5,20 €
Xodimlar soni
98
Ochish
78,95 €
Yuqori
80,40 €
Past
78,95 €
Bozor kapitali
6,81 mlrd
Oʻrtacha hajm
1,81 ming
Hajmi
189,00
52 haftalik eng yuqori
137,40 €
52 haftalik eng past
60,85 €
Aksiya boʻyicha daromad
-5,20 €
Xodimlar soni
98
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
TradingView
·
2 kun oldin
Abivax SA Stock 12‑Month Price Target Cut to $159.06, Implies 79% Upside
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA haqida
CEOMarc de Garidel | Hartmut J. Ehrlich
Xodimlar soni98
Asos solingan4-dek, 2013
Bosh ofislar-
Sektor-
Veb-saytabivax.com